Treatment Clinical Trials in Tianjin, Tianjin Municipality
17 recruitingTianjin, Tianjin Municipality, China
Showing 1–17 of 17 trials
Recruiting
Phase 2
Rituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)
TreatmentImmune Thrombocytopenia
Institute of Hematology & Blood Diseases Hospital, China160 enrolled1 locationNCT07234019
Recruiting
Phase 2
Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)
TreatmentImmune Thrombocytopenia
Institute of Hematology & Blood Diseases Hospital, China160 enrolled1 locationNCT07297563
Recruiting
Phase 1Phase 2
Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AML
TreatmentAMLIDH1 Mutation
Institute of Hematology & Blood Diseases Hospital, China29 enrolled1 locationNCT06611839
Recruiting
Phase 2
Anti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)
TreatmentImmune Thrombocytopenia
Institute of Hematology & Blood Diseases Hospital, China20 enrolled1 locationNCT07362199
Recruiting
Phase 2
Anti-CD38 Antibody Treating Pediatric Primary Immune Thrombocytopenia (ITP)
TreatmentImmune Thrombocytopenia
Institute of Hematology & Blood Diseases Hospital, China60 enrolled1 locationNCT06168851
Recruiting
Phase 2
Anti-CD38 Antibody Treating Children With Primary Immune Thrombocytopenia (ITP)
TreatmentImmune Thrombocytopenia
Institute of Hematology & Blood Diseases Hospital, China30 enrolled1 locationNCT06838962
Recruiting
Phase 1Phase 2
A Clinical Study of NAD in the Treatment of Immune Thrombocytopenia
TreatmentImmune Thrombocytopenia
Institute of Hematology & Blood Diseases Hospital, China20 enrolled1 locationNCT06776510
Recruiting
Phase 2
Anti-CD38 Antibody Treating Elderly Patients With Primary Immune Thrombocytopenia (ITP)
TreatmentImmune Thrombocytopenia
Institute of Hematology & Blood Diseases Hospital, China30 enrolled1 locationNCT07063199
Recruiting
Phase 2
Spatial Fragmentation Combined With Low-dose Radiotherapy for Immunotherapy Combined With Chemotherapy-resistant Locally Advanced or Advanced Non-small Cell Lung Cancer
Lung CancersRadiation Treatment for Tumors
Tianjin Medical University Cancer Institute and Hospital84 enrolled1 locationNCT06775678
Recruiting
Phase 2
Dose-attenuated IST and Hetrombopag in Elderly (≥65 Years) Patients With Severe Aplastic Anemia
Elderly (People Aged 65 or More)Sever Aplastic AnaemiaImmunosuppressive Treatment
Institute of Hematology & Blood Diseases Hospital, China65 enrolled1 locationNCT07010237
Recruiting
Phase 2
An Open, Exploratory Clinical Study of CM336 in the Treatment of Immune Thrombocytopenia
TreatmentImmune Thrombocytopenia (ITP)
Institute of Hematology & Blood Diseases Hospital, China20 enrolled1 locationNCT06799611
Recruiting
Phase 2
A Prospective, One-arm and Open Clinical Study of Zanubrutinib in the Treatment of Immune Thrombocytopenia
TreatmentImmune Thrombocytopenia
Institute of Hematology & Blood Diseases Hospital, China30 enrolled1 locationNCT05214391
Recruiting
Phase 2
Safety and Efficacy of Zanubrutinib in the Treatment of Antiphospholipid Syndrome With Secondary Thrombocytopenia
TreatmentThrombocytopeniaAntiphospholipid Syndrome
Institute of Hematology & Blood Diseases Hospital, China10 enrolled2 locationsNCT05199909
Recruiting
Phase 2
Anti-CD38 Antibody Treating Evans Syndrome
TreatmentEvan Syndrome
Institute of Hematology & Blood Diseases Hospital, China10 enrolled1 locationNCT06014775
Recruiting
Not Applicable
TACS on High-inflammatory and Refractory Depression
InflammationTreatment Resistant Depression (TRD)
Tianjin Anding Hospital52 enrolled1 locationNCT06812923
Recruiting
Ischemic Post-conditioning in the Treatment of Acute Ischemic Stroke
Acute Ischemic StrokeLarge Vessel OcclusionIntracranial Artery Occlusion With Cerebral Infarction+1 more
Ming Wei200 enrolled1 locationNCT06456437
Recruiting
Phase 3
A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma
Treatment-naїve Mantle Cell Lymphoma
Beijing InnoCare Pharma Tech Co., Ltd.356 enrolled22 locationsNCT05051891